Citations

Clear

6274 citation(s) found for "To, Andrew".

The Concept of Minimal Residual Disease in the Treatment and Staging of Vitreoretinal Lymphoma
Stacey, Andrew W. , Pulido, José S.

Mayo Clinic

Retina | May 13, 2020 | Volume: 40 | Issue: 7 | Pages: 1213-1214

10.1097/iae.0000000000002851 | PMID 32404846 Get It

Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location
Labadie, Julia , Harrison, Tabitha A. , Banbury, Barbara L. , Amtay, Efrat L, Bernd, Sonja, Brenner, Hermann , Campbell, Peter T. , Cao, Yin , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Gunter, Marc J. , Hoffmeister, Michael , Moreno, Vı́ctor , Murphy, Neil , Phipps, Amanda I. , Slattery, Martha L. , Thibodeau, Stephen N. , Guelpen, Bethany Van , Zaidi, Syed Hassan Ejaz , Peters, Ulrike , Labadie, Julia D , Banbury, Barbara , Campbell, Peter T , Cao, Yin , Chang-Claude, Jenny , English, Dallas R , Gunter, Marc J , Hoffmeister, Michael , Jenkins, Mark A , Milne, Roger L , Moreno, Victor , Ogino, Shuji , Sakoda, Lori C , Sun, Wei , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Murphy, Neil , Buchanan, Daniel D. , Chan, Andrew T. , English, Dallas R. , Giles, Graham G. , Hsu, Li , Jenkins, Mark A. , Lin, Yi , Milne, Roger L. , Sakoda, Lori C. , Southey, Melissa C. , Sun, Wei , Newcomb, Polly A.

Mayo Clinic

JNCI Cancer Spectrum | May 13, 2020 | Volume: 4 | Issue: 5 | Pages: No page available

10.1093/jncics/pkaa042 | PMID 32923935 Get It

AbstractBackgroundPostmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly defined tumor subtypes and tumor location.MethodsWe pooled data on tumor subtypes (microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, pathway: adenoma-carcinoma, alternate, serrated), tumor location (proximal colon, distal colon, rectum), and HT use among 8220 postmenopausal women (3898 CRC cases and 4322 controls) from 8 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CIs) for the association of ever vs never HT use with each tumor subtype compared with controls. Models were adjusted for study, age, body mass index, smoking status, and CRC family history. All statistical tests were 2-sided.ResultsAmong postmenopausal women, ever HT use was associated with a 38% reduction in overall CRC risk (OR =0.62, 95% CI = 0.56 to 0.69). This association was similar according to microsatellite instability, CpG island methylator phenotype and BRAF or KRAS status. However, the association was attenuated for tumors arising through the serrated pathway (OR = 0.81, 95% CI = 0.66 to 1.01) compared with the adenoma-carcinoma pathway (OR = 0.63, 95% CI = 0.55 to 0.73; Phet =.04) and alternate pathway (OR = 0.61, 95% CI = 0.51 to 0.72). Additionally, proximal colon tumors had a weaker association (OR = 0.71, 95% CI = 0.62 to 0.80) compared with rectal (OR = 0.54, 95% CI = 0.46 to 0.63) and distal colon (OR = 0.57, 95% CI = 0.49 to 0.66; Phet =.01) tumors.ConclusionsWe observed a strong inverse association between HT use and overall CRC risk, which may predominantly reflect a benefit of HT use for tumors arising through the adenoma-carcinoma and alternate pathways as well as distal colon and rectal tumors.
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
Brazauskas, Ruta , Tecca, Heather R. , Bo‐Subait, Stephanie, Buchbinder, David , Battiwala, Minoo, Phelan, Rachel , Broglie, Larisa , Abraham, Allistair , Keating, Amy K. , Daly, Andrew , Wirk, Baldeep , Alter, Blanche P. , Üstün, Celalettin , Freytes, César O. , Beitinjaneh, Amer , Duncan, Christine , Copelan, Edward A. , Hildebrandt, Gerhard , Murthy, Hemant S. , Auletta, Jeffery J. , Page, Kristin , Vrooman, Lynda M. , Norkin, Maxim , Byrne, Michael , Kamani, Naynesh , Rezvani, Andrew R. , Farhadfar, Nosha , Mehta, Parinda A. , Hematti, Peiman , Shaw, Peter J. , Kamble, Rammurti T., Schears, Raquel M. , Hayashi, Robert J. , Mayo, Samantha , Rotz, Seth J. , Badawy, Sherif M. , Ganguly, Siddhartha , Pavletic, Steven Z. , Prestidge, Tim , Inamoto, Yoshihiro , Shaw, Bronwen E. , Satwani, Prakash , Battiwalla, Minoo , Schears, Raquel, Murthy, Hemant S , Badawy, Sherif M , Broglie, Larisa A , Battiwalla, Minoo , Auletta, Jeffery J , Hematti, Peiman , Kahn, Justine M , Flowers, Mary E.D. , Savani, Bipin N. , George, Biju , Lazarus, Hillard M. , Myers, Kasiani , Williams, Kirsten M. , Díaz, Miguel Ángel , Bhatt, Neel S. , Olsson, Richard F. , Gale, Robert Peter , Chhabra, Saurabh , Nishihori, Taiga , Agrawal, Vaibhav , Hogan, William J.

Mayo Clinic

Blood Advances | May 12, 2020 | Volume: 4 | Issue: 9 | Pages: 2084-2094

10.1182/bloodadvances.2019000839 | PMID 32396620 Get It

Abstract We examined the risk of subsequent neoplasms (SNs) and late mortality in children and adolescents undergoing allogeneic hematopoietic cell transplantation (HCT) for nonmalignant diseases (NMDs). We included 6028 patients (median age, 6 years; interquartile range, 1-11; range, <1 to 20) from the Center for International Blood and Marrow Transplant Research (1995-2012) registry. Standardized mortality ratios (SMRs) in 2-year survivors and standardized incidence ratios (SIRs) were calculated to compare mortality and SN rates with expected rates in the general population. Median follow-up of survivors was 7.8 years. Diagnoses included severe aplastic anemia (SAA; 24%), Fanconi anemia (FA; 10%), other marrow failure (6%), hemoglobinopathy (15%), immunodeficiency (23%), and metabolic/leukodystrophy syndrome (22%). Ten-year survival was 93% (95% confidence interval [95% CI], 92% to 94%; SMR, 4.2; 95% CI, 3.7-4.8). Seventy-one patients developed SNs (1.2%). Incidence was highest in FA (5.5%), SAA (1.1%), and other marrow failure syndromes (1.7%); for other NMDs, incidence was <1%. Hematologic (27%), oropharyngeal (25%), and skin cancers (13%) were most common. Leukemia risk was highest in the first 5 years posttransplantation; oropharyngeal, skin, liver, and thyroid tumors primarily occurred after 5 years. Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95% CI, 8.9-13.9) compared with the general population. We report excellent long-term survival and low SN incidence in an international cohort of children undergoing HCT for NMDs. The risk of SN development was highest in patients with FA and marrow failure syndromes, highlighting the need for long-term posttransplantation surveillance in this population.
Survival following allogeneic transplant in patients with myelofibrosis
Gowin, Krisstina , Ballen, Karen K. , Ahn, Kwang Woo , Hu, Zhen‐Huan , Ali, Haris , Arcasoy, Murat O. , Devlin, Rebecca, Coakley, Maria , Gerds, Aaron T. , Jain, Tania , Kandarpa, Malathi , Komrokji, Rami S. , Luber, Kierstin, Michaelis, Laura C. , Patches, Sarah, Pariser, Ashley, Rampal, Raajit K. , Stein, Brady L. , Verstovšek, Srđan , Wadleigh, Martha , Aljurf, Mahmoud , Avalos, Belinda R. , Bashey, Asad, Beitinjaneh, Amer , Černý, Jan , Copelan, Edward A. , DeFilipp, Zachariah , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hashmi, Shahrukh K. , Kharfan‐Dabaja, Mohamed A. , Kindwall‐Keller, Tamila L. , Kröger, Nicolaus , Litzow, Mark R. , Marks, David I. , Nathan, Sunita , Pawarode, Attaphol , Rowe, Jacob M. , Savoie, Mary Lynn , Seo, Sachiko , Solh, Melhem , Tamari, Roni , Verdonck, Leo F. , Alyea, Edwin P. , Sobecks, Ronald , Scott, Bart L. , Nakamura, Ryotaro , Saber, Wael , Kroger, Nicolaus , Davenport, Ashley Pariser , Gerds, Aaron T , Jain, Tania , Gadalla, Shahinaz M , Verstovsek, Srdan , Komrokji, Rami S , Kroger, Nicolaus , Kröger, Nicolaus , Green, Michael, Gupta, Vikas , Hobbs, Gabriela , Kuykendall, Andrew , Masárová, Lucia , Talpaz, Moshe , Agrawal, Vaibhav , Díaz, Miguel Ángel , Bacher, Ulrike , Chhabra, Saurabh , Cutler, Corey S. , Grunwald, Michael R. , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Olsson, Richard F. , Savani, Bipin N. , Yared, Jean A. , Popat, Uday R , Mesa, Ruben A.

Mayo Clinic

Blood Advances | May 8, 2020 | Volume: 4 | Issue: 9 | Pages: 1965-1973

10.1182/bloodadvances.2019001084 | PMID 32384540 Get It

Abstract Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.
OR29-05 A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes
Mukaddam, Mona Al , Pignolo, Robert J. , Cunto, Carmen De , Rocco, Maja Di , Strahs, Andrew , Marino, Rose , Kaplan, Frederick S. , Kaplan, Frederick S , Baujat, Geneviève , Brown, Matthew , Hsiao, Edward C. , Keen, Richard , Sang, Kim‐Hanh Le Quan

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.254 Get It

Abstract Background: FOP is an ultra-rare, severely disabling genetic disorder characterized by episodic flare-ups and heterotopic ossification (HO) leading to restricted movement, physical disability, and early death. FOP may initially be misdiagnosed in ~90% of individuals leading to unnecessary and often harmful interventions. Patients with FOP are diagnosed and managed by multiple specialties, including endocrinologists. Data from an ongoing, prospective, longitudinal, global, natural history study (NCT02322255) were used to investigate the progression of FOP, HO formation, and impact on physical functioning over time. We present results from the first 12 months of the 3-year study. Methods: Males and females with FOP and a documented ACVR1 R206H mutation participated. HO volume was assessed by low-dose whole body computed tomography (WBCT) scan, excluding the head. All imaging was interpreted at a blinded, central laboratory using pre-specified procedures. Functional outcomes were evaluated using the Cumulative Analogue Joint Involvement Scale (CAJIS; for each joint: score=0 represents <10% involvement, score=1 represents 10–90% involvement, and score=2 represents >90% ankylosed across 15 major joints; total score range 0 to 30 [higher scores indicate more severe mobility limitations]) and the FOP Physical Function Questionnaire (FOP-PFQ; percent total score). Changes from Baseline at Month 12 were evaluated for new HO volume, CAJIS, and FOP-PFQ. Results: Of 114 participants (pts) with Baseline data, 99 (4 to 56 years at enrollment; mean 17 years of age; 56% male) also had a Month 12 assessment. A total of 93 pts had evaluable WBCT scans at Baseline and Month 12 and were included in the HO analysis. In total, 40% (37/93) of pts had new HO over 12 months; the mean volume of new HO in these pts was 57,706 mm3 (SD=100,079 mm3; median=20,753 mm3; range: 522 to 438,826 mm3). Of the pts with new HO, 65% (24/37) reported at least one flare-up (mean rate of 2.3 flare-ups/year). Over 12 months, 60% (56/93) of pts did not have new HO; 43% (24/56) of them reported at least one flare-up (mean rate of 1.8 flare-ups/year). Mean changes from Baseline in CAJIS and FOP-PFQ were minimal: CAJIS: 0.6 (SD=2.4; median=1.0; n=99) and FOP-PFQ: 4.4% (SD=11.2; median=3.7%; n=90); and were similar across pts with or without new HO. Conclusions: In participants with FOP, although deterioration of physical function is expected over a patient’s lifetime, CAJIS and FOP-PFQ scores did not worsen significantly in the relative short-term of this study. However, HO volume, quantified by WBCT, increased over the course of 12 months. These results show that measuring HO may be a viable way to monitor changes in FOP over short periods of time.
Open versus minimally invasive decompression for low-grade spondylolisthesis: analysis from the Quality Outcomes Database
Bisson, Erica F. , Mummaneni, Praveen V. , Virk, Michael S. , Knightly, John J. , Alvi, Mohammed Ali , Chan, Andrew K. , Glassman, Steven D. , Foley, Kevin T. , Slotkin, Jonathan R., Potts, Eric A. , Shaffrey, Mark E., Shaffrey, Christopher I. , Haid, Regis W., Fu, Kai-Ming, Wang, Michael Y. , Park, Paul , Asher, Anthony L. , Bydon, Mohamad , Alvi, Mohammed Ali , Goyal, Anshit , Guan, Jian

Mayo Clinic

Journal of Neurosurgery: Spine | May 8, 2020 | Volume: 33 | Issue: 3 | Pages: 349-359

10.3171/2020.3.spine191239 | PMID 32384269 Get It

OBJECTIVELumbar decompression without arthrodesis remains a potential treatment option for cases of low-grade spondylolisthesis (i.e., Meyerding grade I). Minimally invasive surgery (MIS) techniques have recently been increasingly used because of their touted benefits including lower operating time, blood loss, and length of stay. Herein, the authors analyzed patients enrolled in a national surgical registry and compared the baseline characteristics and postoperative clinical and patient-reported outcomes (PROs) between patients undergoing open versus MIS lumbar decompression.METHODSThe authors queried the Quality Outcomes Database for patients with grade I lumbar degenerative spondylolisthesis undergoing a surgical intervention between July 2014 and June 2016. Among more than 200 participating sites, the 12 with the highest enrollment of patients into the lumbar spine module came together to initiate a focused project to assess the impact of fusion on PROs in patients undergoing surgery for grade I lumbar spondylolisthesis. For the current study, only patients in this cohort from the 12 highest-enrolling sites who underwent a decompression alone were evaluated and classified as open or MIS (tubular decompression). Outcomes of interest included PROs at 2 years; perioperative outcomes such as blood loss and complications; and postoperative outcomes such as length of stay, discharge disposition, and reoperations.RESULTSA total of 140 patients undergoing decompression were selected, of whom 71 (50.7%) underwent MIS and 69 (49.3%) underwent an open decompression. On univariate analysis, the authors observed no significant differences between the 2 groups in terms of PROs at 2-year follow-up, including back pain, leg pain, Oswestry Disability Index score, EQ-5D score, and patient satisfaction. On multivariable analysis, compared to MIS, open decompression was associated with higher satisfaction (OR 7.5, 95% CI 2.41–23.2, p = 0.0005). Patients undergoing MIS decompression had a significantly shorter length of stay compared to the open group (0.68 days [SD 1.18] vs 1.83 days [SD 1.618], p < 0.001).CONCLUSIONSIn this multiinstitutional prospective study, the authors found comparable PROs as well as clinical outcomes at 2 years between groups of patients undergoing open or MIS decompression for low-grade spondylolisthesis.
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
Ansell, Stephen M. , Flinn, Ian W. , Taylor, Matthew H. , Šikić, Branimir I. , Brody, Joshua , Nemunaitis, John , Feldman, Andrew L. , Hawthorne, Thomas, Rawls, Tracey, Keler, Tibor , Yellin, Michael , Feldman, Andrew, Feldman, Andrew L , Nemunaitis, John J , Flinn, Ian W , Brody, Joshua D , Taylor, Matthew H.

Mayo Clinic

Blood Advances | May 7, 2020 | Volume: 4 | Issue: 9 | Pages: 1917-1926

10.1182/bloodadvances.2019001079 | PMID 32380537 Get It

Abstract CD27, a costimulatory molecule on T cells, induces intracellular signals mediating cellular activation, proliferation, effector function, and cell survival on binding to its ligand, CD70. Varlilumab, a novel, first-in-class, agonist immunoglobulin G1 anti-CD27 antibody, mediates antitumor immunity and direct killing of CD27+ tumor cells in animal models. This first-in-human, dose-escalation, and expansion study evaluated varlilumab in patients with hematologic malignancies. Primary objectives were to assess safety and the maximum tolerated and optimal biologic doses of varlilumab. Secondary objectives were to evaluate pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. In a 3 + 3 dose-escalation design, 30 patients with B-cell (n = 25) or T-cell (n = 5) malignancies received varlilumab (0.1, 0.3, 1, 3, or 10 mg/kg IV) as a single dose with a 28-day observation period, followed by weekly dosing (4 doses per cycle, up to 5 cycles, depending on tumor response). In an expansion cohort, 4 additional patients with Hodgkin lymphoma received varlilumab at 0.3 mg/kg every 3 weeks (4 doses per cycle, up to 5 cycles). No dose-limiting toxicities were observed. Treatment-related adverse events, generally grade 1 to 2, included fatigue, decreased appetite, anemia, diarrhea, and headache. Exposure was linear and dose-proportional across dose groups and resulted in increases in proinflammatory cytokines and soluble CD27. One patient with stage IV Hodgkin lymphoma experienced a complete response and remained in remission at &gt;33 months with no further anticancer therapy. These data support further investigation of varlilumab for hematologic malignancies, particularly in combination approaches targeting nonredundant immune regulating pathways. This trial was registered at www.clinicaltrials.gov as #NCT01460134.
Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting
Navari, Rudolph M. , Pywell, Cameron, White, Patrick , Dodge, Andrew , Albany, Costantine , Loprinzi, Charles L. , Dodge, Andrew B, Le‐Rademacher, Jennifer

Mayo Clinic

JAMA Oncology | May 7, 2020 | Volume: 6 | Issue: 6 | Pages: 895

10.1001/jamaoncol.2020.1052 | PMID 32379269 Get It

Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Holtan, Shernan G. , Wang, Tao , Hemmer, Michael, Arora, Mukta , Couriel, Daniel R. , Pidala, Joseph, Abdel‐Azim, Hisham , Ahmed, Ibrahim , Al‐Homsi, A. Samer, Aljurf, Mahmoud , Antin, Joseph H. , Askar, Medhat , Auletta, Jeffery J. , Daly, Andrew , DeFilipp, Zachariah , Gajewski, James , Hematti, Peiman , Hildebrandt, Gerhard , Inamoto, Yoshihiro , Martino, Rodrigo , Majhail, Navneet S. , Marks, David I. , Pawarode, Attaphol , Prestidge, Tim , Rangarajan, Hemalatha G. , Ringdén, Olle , Saad, Ayman , Schoemans, Hélène , Seo, Sachiko , Solh, Melhem , Spitzer, Thomas R. , Storek, Jan , Verdonck, Leo F. , Wirk, Baldeep , Cahn, Jean‐Yves , Weisdorf, Daniel J. , Saad, Ayman , Ringden, Olov , Weisdorf, Dan , Majhail, Navneet S , Martino, Rodrigo , Holtan, Shernan , Auletta, Jeffery J , Hematti, Peiman , Mehta, Rohtesh S. , Spellman, Stephen R. , Alousi, Amin Majid , Agrawal, Vaibhav , Bhatt, Vijaya Raj , Chee, Lynette Chui Yen , Chhabra, Saurabh , Gale, Robert Peter , Gergis, Usama , Hogan, William J. , Nishihori, Taiga , Olsson, Richard F. , Díaz, Miguel Ángel , Savani, Bipin N. , Schultz, Kirk R. , Teshima, Takanori , Yared, Jean A.

Mayo Clinic

Journal of Clinical Oncology | May 4, 2020 | Volume: 38 | Issue: 18 | Pages: 2062-2076

10.1200/jco.19.00396 | PMID 32364845 Get It

PURPOSE There is no consensus on the best choice of an alternative donor (umbilical cord blood [UCB], haploidentical, one-antigen mismatched [7/8]–bone marrow [BM], or 7/8-peripheral blood [PB]) for hematopoietic cell transplantation (HCT) for patients lacking an HLA-matched related or unrelated donor. METHODS We report composite end points of graft-versus-host disease (GVHD)–free relapse-free survival (GRFS) and chronic GVHD (cGVHD)–free relapse-free survival (CRFS) in 2,198 patients who underwent UCB (n = 838), haploidentical (n = 159), 7/8-BM (n = 241), or 7/8-PB (n = 960) HCT. All groups were divided by myeloablative conditioning (MAC) intensity or reduced intensity conditioning (RIC), except haploidentical group in which most received RIC. To account for multiple testing, P < .0071 in multivariable analysis and P < .00025 in direct pairwise comparisons were considered statistically significant. RESULTS In multivariable analysis, haploidentical group had the best GRFS, CRFS, and overall survival (OS). In the direct pairwise comparison of other groups, among those who received MAC, there was no difference in GRFS or CRFS among UCB, 7/8-BM, and 7/8-PB with serotherapy (alemtuzumab or antithymocyte globulin) groups. In contrast, the 7/8-PB without serotherapy group had significantly inferior GRFS, higher cGVHD, and a trend toward worse CRFS (hazard ratio [HR], 1.38; 95% CI, 1.13 to 1.69; P = .002) than the 7/8-BM group and higher cGVHD and trend toward inferior CRFS (HR, 1.36; 95% CI, 1.14 to 1.63; P = .0006) than the UCB group. Among patients with RIC, all groups had significantly inferior GRFS and CRFS compared with the haploidentical group. CONCLUSION Recognizing the limitations of a registry retrospective analysis and the possibility of center selection bias in choosing donors, our data support the use of UCB, 7/8-BM, or 7/8-PB (with serotherapy) grafts for patients undergoing MAC HCT and haploidentical grafts for patients undergoing RIC HCT. The haploidentical group had the best GRFS, CRFS, and OS of all groups.
Group 2 Innate Lymphoid Cells Promote Development of T Follicular Helper Cells and Initiate Allergic Sensitization to Peanuts
Krempski, James , Iijima, Koji, McKenzie, Andrew N. J. , Kita, Hirohito , Krempski, James W , Kita, H , Kobayashi, Takao

Mayo Clinic

The Journal of Immunology | May 4, 2020 | Volume: 204 | Issue: 12 | Pages: 3086-3096

10.4049/jimmunol.2000029 | PMID 32366582 Get It

Abstract Peanut allergy is a growing public concern; however, little is known about the immunological mechanism(s) that initiate the disease process. Our knowledge is also limited regarding the role of group 2 innate lymphoid cells (ILC2s) in regulating humoral immunity. To fill these major gaps in our knowledge, we investigated the immunological mechanisms involved in peanut allergen sensitization by using mouse models. To mimic environmental exposure in humans, naive BALB/c mice were exposed to peanut flour by inhalation without any exogenous adjuvants. When exposed to peanut flour, naive mice developed T follicular helper (Tfh) cells in their lung draining lymph nodes and produced IgE Abs to peanuts. Mice deficient in IL-13 showed decreased numbers of Tfh cells and germinal center B cells and produced significantly fewer IgE Abs. IL-13 was necessary and sufficient for induction of CD11c+ MHC class IIhi dendritic cells that are implicated in Tfh cell development. Importantly, lung ILC2s served as a predominant early source of IL-13 when naive mice were exposed to peanut flour. Furthermore, mice that are deficient in lung ILC2s by bone marrow transfer from Rorasg/sg mice or by genetic manipulation produced significantly fewer IgE Abs to peanuts compared with control mice. These findings suggest lung ILC2s that serve as a rapid source of IL-13 upon allergen exposure play a major role in Tfh cell development, IgE Ab production, and initiation of peanut allergy.